EN DE
Watch IceCure Medical Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

IceCure Medical Ltd (ICCM) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of IceCure Medical Ltd stock $1.42, price $0.73, upside +94.5%, quality 37 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Israel · ISIN IL0011224156

IM IceCure Medical Ltd logo Thin data Nov 14, 2026

IceCure Medical Ltd

ICCM · US

Cheap (49% below fair value), but weak company and price moving sideways: meets 1 of 3 rules.

Get notified free when this changes
Fair value $1.42 · Strongly undervalued 
Revenue last quarter +73% vs. a year ago. 
Price moving sideways (no uptrend) 
Mixed vs. peers (4/7) 
Quality 37/100 
Weak Growth (revenue 5y −3.7 %/yr in USD) 
Negative free cash flow 
Narrow moat 8/100
Recent news mostly negative 
Thin data 
⚠ Dilution
Watch IceCure Medical Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$333.51 $0.6807 Fair Value $1.42 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $0.6807 – $333.51 · fair‑value band $0.9435 – $1.78 · the $0.7300 price screens below the $1.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow IceCure Medical in your weekly email

Every Wednesday you see whether IceCure Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.

Show moreShow less

The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics.

IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

Stock analysis

IceCure Medical Ltd (ICCM) currently trades at $0.7300, while our model-based Fair Value estimate is $1.42, implying the stock looks roughly 49% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.9435 (bear) to $1.78 (bull), the price of $0.7300 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

IceCure Medical Ltd reported revenue of $3.4M in FY2025 versus $4.1M in FY2021, a compound −4.9%/yr. Reported net income was −$15.1M in FY2025.

Key figures

Market cap $3.4M Micro · P/S ratio 0.80 · EPS (TTM) $−6.84 · Return on equity −228% · Return on assets (EBIT) −82.8% (5-year average) · Operating margin −488% · Revenue (TTM) $3.9M · Revenue growth (YoY) +72.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (medium confidence).

What moves the price

The share trades about 97% below its 52-week high and 7% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 95%, ICCM screens cheaper than that median.

Fair Value models

Bear $0.9435 Fair Value $1.42 Bull $1.78
Price $0.7300 · Upside +94.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $1.11 $1.67 $2.09 52
All 1 models by family
Asset-Based
NCAV (Graham) $1.11 $1.67 $2.09 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.7%
Start year 2020 (pandemic). Over 10 years: +16.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−106.8% (2020) → −446.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ICCM, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (37 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.

Compare IceCure Medical Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside +94.5% · Top 25%
Profitability
Return on assets −108.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 72.8% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.37× · Cheapest 25%
P/S (12 months) 0.86× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 17
FUTURE (revenue growth)100 · sector 46
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $340.60 +10% vs ICCM
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs ICCM
DexCom, Inc DXCM $83.33 $91.66 +10% vs ICCM
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.30 ¥197.34 +7% vs ICCM
STERIS plc STE $264.32 $281.90 +7% vs ICCM
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs ICCM
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs ICCM
Medtronic plc MDT $102.86 $74.90 −27% vs ICCM
Abbott Laboratories, ABT $108.52 $75.28 −31% vs ICCM
Koninklijke Philips N.V PHIA €27.54 €15.23 −45% vs ICCM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IceCure Medical Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "IceCure Medical Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ICCM

Frequently asked questions

Is IceCure Medical Ltd (ICCM) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of $1.42 versus a price of $0.7300, about +95% upside (undervalued).
What is the fair value of ICCM?
Our model-based fair value for IceCure Medical Ltd is $1.42 (as of Nov 14, 2026), built from audited fundamentals. The current price: $0.7300.
What is the quality score of ICCM?
IceCure Medical Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IceCure Medical Ltd (ICCM)?
Our model-based price target is the fair value of $1.42 (as of Nov 14, 2026) from 1 valuation models. Cautious scenario $0.9435, optimistic scenario $1.78. It is a calculation from audited fundamentals, not an analyst target.
What is the IceCure Medical Ltd stock forecast for 2026?
Our models put fair value at $1.42, about +95% upside versus a price of $0.7300 (undervalued). Cautious scenario $0.9435, optimistic scenario $1.78. The calculation is refreshed regularly with new filings.
What is the revenue of IceCure Medical Ltd (ICCM)?
IceCure Medical Ltd reported trailing-twelve-month revenue of about $3.9M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of IceCure Medical Ltd (ICCM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IceCure Medical Ltd it is $1.42 per share (as of Nov 14, 2026), against a price of $0.7300. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is IceCure Medical Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, ICCM trades below its calculated fair value: price $0.7300, fair value $1.42, a gap of about +95% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ICCM?
No. The price is what the market pays today ($0.7300); the fair value is what the company's own numbers justify ($1.42). For IceCure Medical Ltd the two are $0.6895 per share apart. That gap is exactly why we show both numbers side by side.
How much is IceCure Medical Ltd worth?
The market values IceCure Medical Ltd at about $3.4M (market capitalisation, as of Nov 14, 2026). Per share that is $0.7300; our models calculate a fair value of $1.42 per share.
What do the bullish and bearish scenarios say about ICCM?
Our models span a range for IceCure Medical Ltd: cautious scenario $0.9435, base $1.42, optimistic $1.78 per share (as of Nov 14, 2026, price $0.7300). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of IceCure Medical Ltd (ICCM)?
Balance-sheet figures for IceCure Medical Ltd (as of Nov 14, 2026): return on equity −228.3%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is ICCM from its 52-week high?
IceCure Medical Ltd trades at $0.7300, about 97% below its 52-week high of $21.90 and 7% above the low of $0.6807 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $1.42 is for.
Which stocks are comparable to IceCure Medical Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IceCure Medical Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price $0.7300, calculated fair value $1.42 (+95%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ICCM calculated?
We run IceCure Medical Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.42 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. IceCure Medical Ltd currently trades 49% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IceCure Medical Ltd (ICCM)?
The closing price on Nov 13, 2026 was $0.7300. Our model-based fair value is $1.42, about +95% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IceCure Medical Ltd right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.9435). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.9435 to $1.78) leaves room in how you read the outcome.

Key figures of IceCure Medical Ltd

How large is the market capitalisation of IceCure Medical Ltd (ICCM)?
The market capitalisation of IceCure Medical Ltd is $3.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IceCure Medical Ltd (ICCM)?
The price-to-sales ratio of IceCure Medical Ltd is 0.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IceCure Medical Ltd (ICCM)?
Earnings per share at IceCure Medical Ltd are $−6.84. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of IceCure Medical Ltd (ICCM)?
The return on equity (ROE) of IceCure Medical Ltd is −228% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IceCure Medical Ltd (ICCM)?
On an EBIT basis the return on assets of IceCure Medical Ltd is −82.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IceCure Medical Ltd (ICCM)?
The operating margin of IceCure Medical Ltd is −488% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IceCure Medical Ltd (ICCM)?
Revenue at IceCure Medical Ltd is growing 72.8% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does IceCure Medical Ltd (ICCM) generate?
The free cash flow of IceCure Medical Ltd is −$14.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does IceCure Medical Ltd (ICCM) hold?
IceCure Medical Ltd holds more cash than debt, $8.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch IceCure Medical Ltd in the live analysis

One click puts IceCure Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.